Edison Group
Bull, Bear & Beyond by Edison Group
Discover fresh perspectives in the Bull, Bear & Beyond podcast series by Edison Group. Our longer episodes feature candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation and the opportunities shaping their markets. These discussions offer unique insight into how leaders navigate challenges, drive growth and deliver long-term value for stakeholders. Our 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit. To find out more, please visit: https://www.ediso...
Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: www.edisongroup.com
Autor
Edison Group
Kategoria
Strona podcastu
Ostatni odcinek
18 lis 2026
Gdzie słuchać?
Podcasty w aplikacji Replaio Radio Już wkrótcePodcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów
Odcinki
3. Bull, Bear & Beyond – Regional REIT: executive interview 25.09.2024 16:29
Regional REIT (RGL) is a specialist investor in offices across regional centres of the UK, outside the M25. It is actively managed with a strong focus on income returns. The steep rise in interest rates, combined with uncertainty about the pattern of post-pandemic office use, has seen office values fall significantly. In August, RGL successfully raised more than £100m in new equity, to repay borro...
2. Bull, Bear & Beyond – IRLAB Therapeutics: executive interview 23.09.2024 11:14
"IRLAB Therapeutics (OMX: IRLAB-A) is a Sweden-based biopharma company focused on the development of novel treatments for neurodegenerative diseases, with a particular focus on Parkinson’s disease (PD). The company has a highly active pipeline, with assets spanning all stages of clinical development, from preclinical programmes through to its lead asset, mesdopetam, which is Phase III-ready. *****...
1. Bull, Bear & Beyond – The Biotech Growth Trust in 60 seconds 03.09.2024 1:01
"Edison’s investment companies team recently published a review of The Biotech Growth Trust (BIOG). The trust’s managers Geoff Hsu and Josh Golomb at leading global healthcare specialist OrbiMed are positive on the outlook for biotech stocks. Higher interest rates have pressured the sector’s valuation despite a favourable fundamental industry backdrop, which includes a high level of innovation, el...
Podobne podcasty
Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS